Disclosed is the use of a pharmaceutical composition comprising the analgesic acetaminophen in the manufacture of a medicament for treating nocturia, wherein said acetaminophen is formulated for administration at a daily dose of 1 mg to 2000 mg and wherein said pharmaceutical composition is formulated in a delayed-release formulation or an immediate-release formulation, wherein said pharmaceutical composition further comprises one or more spasmolytics (e.g. carisoprodol, benzodiazepines, baclofen, cyclobenzaprine, metaxalone, methocarbamol, clonidine, dantrolene etc.) , one or more antimuscarinic agents selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine, or one or more antidiuretics (such as antidiuretic hormone (ADH)； angiotensin II； aldosterone； vasopressin； desmopressin； argipressin； lypressin； felypressin； ornipressin； terlipressin； vasopressin receptor agonists； atrial natriuretic peptide (ANP)； C-type natriuretic peptide (CNP) receptor antagonists, e.g. HS-142-1, isatin, anantin, 3G12 monoclonal antibody etc)； somatostatin type 2 receptor antagonists (e.g., somatostatin)). Also disclosed is the use of a pharmaceutical composition in the manufacture of a medicament for treating nocturia wherein the pharmaceutical composition comprises a plurality of active ingredients, wherein said plurality of active ingredients comprise acetaminophen and one or more antimuscarinic agents selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine, wherein said pharmaceutical composition is formulated for immediate-release of said plurality of active ingredients or for delayed-release of said plurality of active ingredients and wherein said acetaminophen is formulated for administration at a daily dose of 50 mg to 2000 mg.
